The role of angiotensin receptor subtypes 1 and 2 was assessed on neointima formation after injury in rat carotid artery. The effects of angiotensin converting enzyme inhibition by perindopril (3 mg • kg" 1 • day" 
T he understanding and therapeutic control of abnormal vascular smooth muscle cell (SMC) growth is of considerable interest since it appears to be a fundamental pathogenetic factor in both hypertension and atherosclerosis. In hypertension, abnormal SMC growth consists mainly of cellular hypertrophy in large arteries, although hyperplasia may also occur in small arteries and arterioles. This differs from atherosclerosis, where focal SMC proliferation into the intima is the dominant feature. SMC proliferation also appears to be involved in some important therapeutic failures, including restenosis after percutaneous angioplasty, which occurs within 6 months in 30-40% of patients, obliteration of venous grafts after coronary bypass surgery, and accelerated coronary atherosclerosis after heart transplant. 1 To mimic these clinical situations, various experimental models have been developed in which myointimal proliferation is produced, usually by vascular injury as a pathogenic factor.
SMC and endothelial integrity appear to be crucial in maintaining the functional and structural properties of the vascular wall. Indeed, arterial injury by balloon catheterization promotes platelet adhesion and progres-sive SMC proliferation in the intima of muscular arteries, which reaches a maximum 2 weeks later. Neointimal formation increases further until 3 months by accumulation of extracellular matrix. The time course of this vascular response has been well characterized in rats. 2 Several experimental studies have implicated the role of the renin-angiotensin system (RAS) in the vascular response to endothelial injury. Chronic treatment with angiotensin converting enzyme (ACE) inhibitors, such as cilazapril, captopril, 3 -4 and ramipril, 3 reduced myointimal thickening induced by balloon injury in rat carotid artery and rat aorta, respectively. This effect was dose dependent, but interestingly, the doses of ACE inhibitors effective in suppressing the neointima formation appeared to be higher than those used to lower blood pressure. 4 This discrepancy suggested the role of local RAS in the pathogenesis of this model. The protective effect of ACE inhibitors appeared to be mediated by the inhibition of angiotensin II (Ang II) production, because simultaneous infusion of Ang II and ACE inhibition restored the proliferative response to vascular injury. 6 Recently, two distinct subtypes of angiotensin binding sites have been identified using specific antagonists and have been classified as subtype 1 (ATj) and subtype 2 (AT 2 ) receptors. Ang II binding to AT t receptors is selectively displaced by DuP 753. 7 ATi receptors have been localized in the vasculature, brain, and adrenal glands and contribute to the peripheral and central regulation of the cardiovascular system and fluid homeostasis. AT 2 receptors have been revealed using specific antagonists such as CGP 42112A and have been found in uterus, kidney, adrenal glands, heart, arteries, and the brain,*" 12 but their physiological roles remain unclear. Studies have shown that in the vascular system of the adult rat, the predominant Ang II receptor is the ATj subtype with low density of AT 2 subtype. 12 However, during development, the ratio of AT, to AT 2 receptors in the vasculature is reversed. 12 The purpose of this study was to investigate the role of AT, and AT 2 angiotensin receptor subtypes in the proliferative response to vascular injury. Perindopril, a potent and long-acting ACE inhibitor, 13 was used to inhibit ACE, and DuP 753 and CGP 42112A were used to selectively block AT, and AT 2 receptors, respectively.
Methods
All procedures were carried out in accordance with the guidelines of the French Ministry of Agriculture for the use and care of laboratory animals.
Cardiovascular Studies
To compare the effects of ACE inhibition versus the blockade of AT, receptors on myointimal formation, it was first essential to determine the equipotency between perindopril and DuP 753 on the RAS. The first series of experiments was designed to select equally effective doses of perindopril and DuP 753 on the RAS after a 20-day chronic treatment. The duration of this treatment was the same as that subsequently used for the histomorphometric studies. Male Wistar rats weighing 400-450 g (Charles Rivers Laboratories, SaintAubin-les-Elboeuf, France) received either perindopril (3 mg • kg" 1 ) and acepromazine (5 mg • kg" 1 ), and the femoral artery and jugular vein were catheterized for arterial pressure measurement and drug administration, respectively. Both catheters were filled with heparinized saline (50 mg • ml" 1 ) and were tunneled subcutaneously to exit at the back of the neck. Twenty-four hours after the last administration (day 21), mean arterial pressure (MAP) and heart rate (HR) were monitored in conscious, freely moving rats. Pulse pressure and MAP were displayed on a model ES1000 recorder (Gould Inc., Ballainvilliers, France). HR was determined by a Gould Biotach cardiotachometer providing the derivative function of arterial pulse pressure. ACE and AT, receptor activities in the different groups were assessed by the pressor effects produced by intravenous injection of angiotensin I (Ang I) (300 ng • kg" 1 ) and Ang II (100 ng • kg" 1 ), respectively.
To evaluate the activity level of the RAS at the time of balloon injury in rats chronically treated with perindopril and DuP 753, we performed the following protocol. After 4 days of oral treatment with either perindopril (3 mg • kg" 1 • day" 1 ), DuP 753 (5 and 30 mg • kg" 1 • day" 1 ), or their respective vehicles (1 ml • kg" 1 • day" 1 ), male Wistar rats were anesthetized, and arterial and venous catheters were implanted as described above. Oral drug treatments were continued for the following 2 days. On day 7, MAP and HR were monitored, and the oral potency and duration of ACE inhibition and AT, receptor blockade after perindopril and DuP 753 treatment, respectively, were examined as follows. After a 1-hour stabilization period, Ang I (300 ng • kg" 1 ) or Ang II (100 ng • kg-1 ) was injected intravenously before and after oral administration of either perindopril (3 mg • kg" 1 ) or DuP 753 (5 and 30 mg • kg" 1 ). The effectiveness of the inhibition was examined for 6 hours and at 24 hours after administration.
Histomorphometric Studies
The first series of experiments was designed to compare the effects of ACE inhibition versus the blockade of AT, receptors on neointima formation after arterial injury. For this study, six groups were used. Male Wistar rats weighing 400-450 g (Charles Rivers) were treated for 6 days before the endothelial denudation with either perindopril ( The second series of experiments was performed to determine whether AT 2 receptors were involved in the myointimal thickening. In a first experiment, rats received continuous subcutaneous infusion of the specific AT 2 receptor antagonist CGP 42112A (1 mg • kg" 1 • day" 1 ) or its vehicle via osmotic minipumps (models 2ML2, 2ML1, Alzet, Palo Alto, Calif.) for 20 days. As recommended by the manufacturer, the reservoir of the minipump was filled with the solution and incubated in a saline solution at room temperature for 24 hours to assure that the infusion rate was constant After 6 days of subcutaneous infusion, balloon catheterization was performed as reported above. In a second experiment, rats with no drug pretreatment underwent balloon injury of the common carotid artery. At the end of the ballooning procedure (<2 minutes), a Silastic cuff connected by a catheter to an osmotic minipump (Alzet model 2ML2) was placed and secured around the injured artery to deliver a perivascular infusion of either CGP 42112A (1 mg • kg" 1 • day" 1 ) or its vehicle. Fourteen days after endothelial denudation (day 14), all rats were anesthetized by intraperitoneal injection of pentobarbital (60 mg • kg" 1 ). Evans blue (0.5 ml of 0.5% saline solution) was administered intravenously 20 minutes before animals were killed to evaluate the level of endothelial regeneration. The carotid arteries were perfused under a pressure of 90 mm Hg with 10% formaldehyde for 20 minutes and then carefully dissected and left in the same fixative until processed further. The midportion of each carotid artery was used for histological studies, because this region did not show any evidence of endothelial regeneration (positive staining after Evans blue injection). The portion was divided in four segments (2.5 mm length) and embedded in paraffin. Cross sections (5 jun) were prepared and stained with orcein. The distance between two cross sections was 50 /un. Medial and intimal cross-sectional areas were measured with a Biocom computerized image analysis system (HISTO software, Biocom, Les Ulis, France). This system allows an overall analysis of the cross section. For each carotid artery, histomorphometric parameters were averaged from the analysis of 12 cross sections (three cross sections per segment).
Drugs
The drugs used in the study were obtained from the following sources: Ang I, Ang II, and Evans blue from Sigma Chemical Co., St. Quentin, France; ketamine (Imalgene 1000) from Rhdne Merieux, Lyon, France; and acepromazine (Vetranquil 1%) and pentobarbital from Sanofi, Libourne, France. DuP 753 (sodium salt of 
Statistical Analysis
Cardiovascular studies were analyzed by either oneway analysis of variance or two-way analysis of variance with repeated measures or replication. The post hoc test used was the Newman-Keuls test. For histomorphometric studies, statistical analysis was performed by the Student's / test. Data are presented as mean±SEM.
Results

Cardiovascular Studies
The first series of experiments was performed to evaluate the level of RAS activity after 20 days of chronic treatment with perindopril (3 mg • kg" 1 • day" 1 ) and DuP 753 (5 mg • kg"' • day" 1 ). Twenty-four hours after the last administration of the 20-day treatment (equivalent to day 14 in the histomorphometric studies), rats chronically receiving perindopril or DuP 753 showed a significantly lower MAP than their respective control groups. The blood pressure-lowering effects of perindopril and DuP 753 were not significantly different, and basal HR was not changed by either of the two treatments ( Table 1 ). The pressor response produced by intravenous injection of Ang I (300 ng • kg" 1 ) and Ang n (100 ng • kg"') was used to determine the efficacy of perindopril on ACE activity and DuP 753 on the blockade of AT, receptors, respectively. In vehicletreated groups, intravenous injection of Ang I (300 ng • kg" 1 ) produced a pressor response and a reflex bradycardia, which were similar in magnitude to the cardiovascular response mediated by intravenous injection of Ang II (100 ng • kg" 6.0 
Histomorphometric Studies
The results of the histomorphometric studies are illustrated in Figures 3 and 4 . Fourteen days after endothelial injury, a massive proliferation was observed in the intima of the vehicle-treated groups. Hyperplasia was not statistically different among all vehicle-treated groups. The neointima area and the intima/media ratio were significantly reduced by perindopril treatment (-75% and -76%, respectively; /><0.01). In contrast, DuP 753 treatment at 5 mg • kg" 1 • day" 1 did not alter neointimal hyperplasia. In this group, the neointima area and the intima/media ratio were close to those observed in the corresponding vehicle-treated group. Only long-term treatment with high doses of DuP 753 (30 mg • kg" 1 • day" 1 ) significantly attenuated myointimal thickening (-47%). Chronic subcutaneous infusion of CGP 42112A (1 mg • kg" 1 • day" 1 ) did not modify the proliferative response to vascular injury. However, when the same dose of CGP 42112A was constantly infused in the perivascular vicinity of the injured artery, the neointima area and the intima/media ratio were significantly suppressed (78% and 73%, respectively; Discussion Ang II receptors, ACE, 14 and angiotensinogen messenger RNA 15 have been identified in the vascular wall, and several lines of evidence have supported the role of a local RAS in the pathogenesis of neointima formation induced by vascular injury. 34 In rats treated 6 days before injury and continuously for the subsequent 14 days, ACE inhibition by perindopril (3 mg • kg" • day" 1 ) significantly reduced (-76%) myointimal hyperplasia induced by endothelial denudation. These findings were identical to those described for cilazapril (-77%), where the same model of neointima hyperplasia and protocol design were used. 3 In comparison with other ACE inhibitors, perindopril appears to be one of the most potent in suppressing myointimal proliferation since cilazapril and captopril showed similar activity but at much higher doses (10 and 100 mg • kg" 1 , respectively). 3 In this respect, Plissonnier et al 16 have also reported the potency of perindopril on another model of myointimal growth induced by aortic allograft. In this model, low doses of perindopril (1 mg • kg ' p.o., twice daily) significantly decreased intimal thickening.
Because inhibition of ACE was associated with a reduction in neointima formation, decreased Ang II concentration has been suggested to be the cause for this antihyperplastic effect. Chronic infusion of Ang II stimulated DNA synthesis, enhanced the neointima formation, 6 -17 and abolished the protective action of ACE inhibitors on intimal hyperplasia when administered concomitantly. 6 These data strongly supported the role of Ang II in this aberrant vascular response and excluded the contribution of other putative peptides whose accumulation might also result from ACE inhibition. DuP 753 reduced neointima formation induced by balloon injury only when high doses were used. Indeed, at 5 mg • kg" 1 Thus, the effects of ACE inhibition and AT, blockade on myointimal proliferation differ markedly despite a similar level of RAS inhibition. If stimulation of AT] receptors contributed preferentially to the neointima formation, selective blockade of these receptors should have suppressed the hyperplastic response to the same extent as after ACE inhibition. However, the maximal protective activity found with ACE inhibitors (cilazapril, captopril, perindopril) is always superior to that reported for DuP 753 (approximately -8 0 % versus -50%, respectively),
18 regardless of the dose and protocol used. Nonetheless, ACE does not cleave only Ang I but also bradykinin, substance P, and possibly other peptides. Therefore, the accumulation of some of these peptides due to ACE inhibition might be responsible for the effects on vascular proliferation. Thus, inhibition of converting enzyme is known to potentiate the physiological responses of bradykinin. A recent study claimed that part of the antiproliferative effect of ACE inhibition could be attributed to a reduction in the breakdown of bradykinin. 19 Chronic blockade of bradykinin receptors with Hoechst 140 blunted but did not abolish the protective effect of ACE inhibition, suggesting that blockade of Ang II formation and an increase in endogenous kinins would be the mechanisms by which ACE inhibitors suppress the vascular response to injury. 19 Bradykinin could mediate its antiproliferative effect, if any, by stimulating the endothelial release of prostacyclin and endothelium-derived relaxing factor.' 9 However, after vascular injury, the endothelium is totally removed and thus the major source of prostacyclin and endothelium-derived relaxing factor. This finding leaves the debate open and needs to be confirmed by other studies, particularly because bradykinin has been documented to act as a growth factor and to possess mitogenic activity in vitro. 20 " 22 Therefore, increased bradykinin concentration would have been expected to stimulate the vascular response to injury.
The major finding of our study is that AT 2 receptors play an important role in the neointima formation induced by vascular injury in the rat. Chronic blockade of AT 2 receptors by perivascular infusion of CGP 42112A (1 mg • kg" 1 • day" 1 ) markedly reduced the vascular response to balloon catheterization ( -7 3 % , /><0.01). Only CGP 42112A infusion in the perivascular vicinity of the injured carotid artery was able to match the effect of ACE inhibitors on myointimal formation. When the same dose of CGP 42112A was given subcutaneousry, the proliferative response remained unchanged despite a 6-day pretreatment. The inefficacy of CGP 42112A when administered under these conditions could have been explained by heat degradation that would occur by leaving this compound in solution in minipumps at 37°C for 2 weeks. However, this is not the case, because the high-performance liquid chromatogTaphic profile of CGP 42112A from the solution remaining in minipumps after 2 weeks of infusion was identical to the original one (degradation <5%; unpublished observations). The difference of efficacy between these two routes of administration could be due, for instance, to a difference in drug delivery or effective half-life of this compound, but we cannot rule out other possibilities.
Quantitative autoradiographic studies have shown that, in the vascular system of the adult rat, the predominant Ang II receptor is the AT, subtype with low density of AT 2 (30%).
U12 However, the expression of AT 2 receptors is elevated during development, because the number of AT 2 receptors and the AT 2 /AT, receptor ratio are much higher in fetal than in adult rat. This switch in the expression of AT! and AT 2 receptors suggested that AT 2 receptors may play a role in the vascular development. Similar change in the expression of AT, versus AT 2 has been observed in other tissues, such as the skin, where the expression of AT 2 receptors is enhanced during experimentally induced wound healing. 23 The ability of a tissue to switch its proportion of Ang II receptors from AT 2 to AT, has also been reported in the myometrium during ovine pregnancy. 24 Our results indicate not only that AT 2 receptors are involved in myointimal growth but that this pathological vascular response is associated with an increase in AT 2 receptor expression. Overall, the participation of Ang II to vascular response after injury involved both AT, and AT 2 receptor subtypes.
For many years, the role of Ang II in vascular growth has been limited to cell hypertrophy and facilitation of growth factor-induced proliferation. For instance, Geisterfer et al 25 indicated that Ang II induced hypertrophy but not hyperplasia in cultured rat aortic SMCs with a contractile phenotype and stimulated protein synthesis. 26 In SMCs isolated from newborn animals share these characteristics, as opposed to cultured medial SMCs from adult animals, which do not. 31 From these observations arises the possibility that neointimal SMCs could express a fetal phenotype, which would result from the amplification of a subpopulation of medial SMCs. Because AT 2 is widely expressed and is the predominant angiotensin subtype during embryonic life, 12 it is possible that the neointimal cells originating from this subpopulation with fetal properties would express mainly AT 2 receptors. This hypothesis could explain why cultured aortic SMCs originating from normal media show only AT] receptors. 8 Our theory is also consistent with the selectivity of action of Ang II on SMCs of injured arteries. In balloon catheter-injured arteries, Ang II stimulates DNA synthesis and growth more markedly in the neointima than in the media. 17 This histological selectivity in the proliferative response to Ang II could be due to a predominant expression of AT 2 receptors in the neointima of injured arteries.
Intimal thickening in response to arterial injury results from the combination of three major events, including migration of SMCs from the media to the intima, proliferation of intimal SMCs, and production of extracellular matrix. 2 The mechanism by which the blockade of AT, receptors inhibits the development of this vascular lesion could be due to either inhibition of SMC migration from the media to the intima or a decrease of proliferation of intimal SMCs since DuP 753 did not modify the cell density of the neointima. 18 In fact, according to Prescott et al, 32 DuP 753 inhibited both SMC migration and proliferation, because DNA synthesis in medial SMCs was decreased 24-48 hours after injury, and the number of SMCs at day 4 after injury was reduced. At day 4, intimal SMCs are supposed to represent the number of SMCs that have migrated from the media to the intima. Therefore, it would also be interesting to study the mechanism by which AT 2 antagonist suppresses the development of this vascular lesion, to investigate whether the combination of AT, and AT 2 receptor blockade prevents the vascular response more effectively than ACE inhibition alone, and how AT, and AT 2 receptor stimulation could interplay.
The signal-transduction pathway of the AT 2 receptor remains poorly understood. In tissues expressing AT 2 receptors exclusively, it has been shown that this angiotensin receptor subtype is not coupled to G proteins 33 ; does not affect inositol triphosphate production, intracellular calcium mobilization, or adenylate cyclase activity; and is not a receptor mediating intemalization of agonist. 34 However, recent reports indicate that, in neonatal neuronal cells, AT 2 stimulation reduced cyclic GMP, probably through a mechanism involving calcium influx and the activation of cyclic GMP phosphodiesterase, 35 and in astrocytes, it increased prostaglandin synthesis. 36 Interestingly, AT 2 receptors are localized in highly vascularized organs, such as uterus, kidney, brain, heart, and adrenal glands, 8 -11 and recently, a novel physiological role has been reported for AT 2 receptors that could be linked to these observations. Indeed, Le Noble et al 37 demonstrated that Ang II stimulates angiogenesis in the chorioallantoic membrane model in a dose-dependent manner. This effect was blocked by CGP 42112A, suggesting that AT 2 receptors mediated this angiogenic activity. 38 In conclusion, our findings demonstrated for the first time the participation of AT 2 receptors in the processes of excessive repair that lead to lesion formation in response to vascular injury. It remains to be established whether the beneficial effects of AT 2 receptor blockade holds in other species, for example, in swine or primate, 39 -41 in which ACE inhibitors have been reported to be ineffective in suppressing neointima formation. This is an important issue because the recent results of the MERCATOR restenosis trials show that the ACE inhibitor cilazapril does not reduce restenosis after angioplasty, 42 despite a profound effect on the intimal proliferative response to balloon injury in the rat. These negative results in humans correlate well with those observed in swine and primate and support the necessity of studies on other species before the therapeutic relevance of the blockade of AT 2 receptor in restenosis after balloon angioplasty is considered.
